SETD2 and nonpapillary renal cell carcinoma: Metabolic reprogramming caused by SETD2 deletion ultimately accelerates de novo sphingomyelin (SM) synthesis and tumorigenesis during the transition from PKD to ccRCC (Fig. 7).